- Home
- BJRI vs ARVN Comparison
BJRI vs ARVN Comparison
Compare BJRI & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | ARVN |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.2M | 781.0M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BJRI | ARVN |
|---|---|---|
| Price | $36.91 | $13.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 21 |
| Target Price | ★ $44.14 | $15.57 |
| AVG Volume (30 Days) | 314.6K | ★ 743.8K |
| Earning Date | 05-29-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 208.57 | 58.84 |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $3.82 | $1.94 |
| P/E Ratio | $24.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.46 | $5.90 |
| 52 Week High | $47.02 | $18.93 |
Technical Indicators
Market Signals| Indicator | BJRI | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 28.76 | 58.35 |
| Support Level | $33.45 | $11.10 |
| Resistance Level | $38.56 | $13.97 |
| Average True Range (ATR) | 1.92 | 0.83 |
| MACD | -0.56 | 0.10 |
| Stochastic Oscillator | 2.13 | 81.83 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.